Oncogenic Oral Human Papillomavirus Clearance Patterns Over 10 years.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
31 Jan 2024
Historique:
accepted: 29 01 2024
received: 14 10 2023
revised: 06 12 2023
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 31 1 2024
Statut: aheadofprint

Résumé

Effective screening for Oropharyngeal cancer (OPC) is lacking. Four oncogenic HPV clearance definitions were explored to understand long-term natural history for persistent oncogenic oral HPV (oncHPV), the precursor of OPC. Prospective multicenter cohort of participants living with/at-risk for HIV, with oral rinse and gargle samples collected every 6-12 months for up to 10 years and tested for oncHPV. HPV clearance definitions included 1 (clear1), 2 (clear2), 3 (clear3) consecutive negatives, or being negative at last 2 visits (clearlast). Median time to clearance of oncHPV exceeded 2 years for conservative definitions (clear3: 2.38,clearlast: 2.43), but not lenient (clear1:0.68, clear2:1.15). By clear3, most incident infections cleared at 2,5,8 years (55.1%,75.6%,79.1%), contrary to prevalent infections (37.1%,52.5%,59.5%, respectively). In adjusted analysis, prevalent oncHPV, older age, male sex and living with HIV were associated with reduced clearance. Of 1833 subjects screened, 13.8% had prevalent oncHPV and 47.5% of those infections persisted ≥5 years, representing 6.5% of persons screened. Two men with prevalent oHPV16 developed incident OPC (IR=1.62 per 100 person-years,95%CI=0.41,6.4). Many with oHPV16 persisted ≥5 years (and/or developed HPV-OPC) among those with 2 (72.2%), ≥2 of first 3 (65.7%), or 3 (80.0%) consecutive positive oHPV16 tests, but not after 1 (39.4%). In our 10 year study, most incident infections cleared quickly. However, half of prevalent oncHPV persisted ≥5 years, suggesting increased risk with persistent oncHPV at > 2 visits. We identified groups with persistent oncHPV at increased risk of OPC and contextualized risk levels for those with oral HPV16 infection.

Sections du résumé

BACKGROUND BACKGROUND
Effective screening for Oropharyngeal cancer (OPC) is lacking. Four oncogenic HPV clearance definitions were explored to understand long-term natural history for persistent oncogenic oral HPV (oncHPV), the precursor of OPC.
METHODS METHODS
Prospective multicenter cohort of participants living with/at-risk for HIV, with oral rinse and gargle samples collected every 6-12 months for up to 10 years and tested for oncHPV. HPV clearance definitions included 1 (clear1), 2 (clear2), 3 (clear3) consecutive negatives, or being negative at last 2 visits (clearlast).
RESULTS RESULTS
Median time to clearance of oncHPV exceeded 2 years for conservative definitions (clear3: 2.38,clearlast: 2.43), but not lenient (clear1:0.68, clear2:1.15). By clear3, most incident infections cleared at 2,5,8 years (55.1%,75.6%,79.1%), contrary to prevalent infections (37.1%,52.5%,59.5%, respectively). In adjusted analysis, prevalent oncHPV, older age, male sex and living with HIV were associated with reduced clearance. Of 1833 subjects screened, 13.8% had prevalent oncHPV and 47.5% of those infections persisted ≥5 years, representing 6.5% of persons screened. Two men with prevalent oHPV16 developed incident OPC (IR=1.62 per 100 person-years,95%CI=0.41,6.4). Many with oHPV16 persisted ≥5 years (and/or developed HPV-OPC) among those with 2 (72.2%), ≥2 of first 3 (65.7%), or 3 (80.0%) consecutive positive oHPV16 tests, but not after 1 (39.4%).
CONCLUSIONS CONCLUSIONS
In our 10 year study, most incident infections cleared quickly. However, half of prevalent oncHPV persisted ≥5 years, suggesting increased risk with persistent oncHPV at > 2 visits.
IMPACT CONCLUSIONS
We identified groups with persistent oncHPV at increased risk of OPC and contextualized risk levels for those with oral HPV16 infection.

Identifiants

pubmed: 38294704
pii: 734032
doi: 10.1158/1055-9965.EPI-23-1272
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Gypsyamber D'Souza (G)

Johns Hopkins University, Baltimore, Maryland, United States.

Sakshi R Tewari (SR)

Johns Hopkins University, Baltimore, United States.

Tanya Troy (T)

Johns Hopkins University, Baltimore, Maryland, United States.

Jennifer Webster-Cyriaque (J)

National Institute of Dental and Craniofacial Research, United States.

Dorothy J Wiley (DJ)

University of California, Los Angeles, Los Angeles, CA, United States.

Cecile Delille Lahiri (CD)

Emory University School of Medicine, United States.

Frank Joseph Palella (FJ)

Northwestern University, United States.

Maura L Gillison (ML)

The University of Texas MD Anderson Cancer Center, Houston, United States.

Howard D Strickler (HD)

Albert Einstein College of Medicine, Bronx, New York, United States.

Linda Struijk (L)

Viroclinics- DDL a Cerba research company, Rijswijk, Netherlands.

Tim Waterboer (T)

German Cancer Research Center, Heidelberg, Germany.

Ken Ho (K)

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States.

Jennafer Kwait (J)

Whitman-Walker Institute, United States.

Jason Lazar (J)

SUNY Downstate Health Science University, United States.

Kathleen M Weber (KM)

Hektoen Institute of Medicine, United States.

Carole Fakhry (C)

Johns Hopkins University, Baltimore, MD, United States.

Classifications MeSH